59 related articles for article (PubMed ID: 16462031)
1. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
[TBL] [Abstract][Full Text] [Related]
2. Topical Tacrolimus and Mycophenolic Acid Therapy Synergizes with Low Dose Systemic Immunosuppression to Sustain Vascularized Composite Allograft Survival.
Feturi FG; Zhang W; Erbas VE; Dong L; Sahin H; Zhang Z; Oksuz S; Spiess AM; Solari MG; Venkataramanan R; Gorantla VS
J Pharm Sci; 2024 Jun; 113(6):1607-1615. PubMed ID: 38309457
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometry method for mycophenolic acid and its glucuronide determination in saliva samples from children with nephrotic syndrome.
Sobiak J; Resztak M; Sikora W; Zachwieja J; Ostalska-Nowicka D
Pharmacol Rep; 2024 Jun; 76(3):600-611. PubMed ID: 38485859
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Metabolite Trough Concentrations Are Not Well Correlated With Dosing or Adverse Outcomes in Pediatric Heart Transplant Recipients.
Saad MS; Chen J; Salerno D; Corbo H
J Pediatr Pharmacol Ther; 2024 Jun; 29(3):299-305. PubMed ID: 38863858
[TBL] [Abstract][Full Text] [Related]
5. Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate.
Simpson JB; Sekela JJ; Graboski AL; Borlandelli VB; Bivins MM; Barker NK; Sorgen AA; Mordant AL; Johnson RL; Bhatt AP; Fodor AA; Herring LE; Overkleeft H; Lee JR; Redinbo MR
Gut Microbes; 2022; 14(1):2107289. PubMed ID: 35953888
[TBL] [Abstract][Full Text] [Related]
6. Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients.
Ciftci HS; Ayna TK; Calıskan YK; Turkmen A; Gurtekin M
Indian J Clin Biochem; 2013 Apr; 28(2):164-8. PubMed ID: 24426203
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota biotransformation of drug glucuronides leading to gastrointestinal toxicity: Therapeutic potential of bacterial β-glucuronidase inhibition in mycophenolate-induced enteropathy.
Brossier C; Jardou M; Janaszkiewicz A; Firoud D; Petit I; Arnion H; Pinault E; Sauvage FL; Druilhe A; Picard N; Di Meo F; Marquet P; Lawson R
Life Sci; 2024 Jun; 351():122792. PubMed ID: 38857657
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep model.
Leber B; Liebchen U; Rohrhofer L; Weber J; Klaus T; Scheier J; Sucher R; Stiegler P
Front Med (Lausanne); 2023; 10():1258661. PubMed ID: 37928476
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 Antibody and Calcineurin Inhibitor Combination Therapy Effectively Suppresses Antibody-Mediated Rejection in Murine Orthotopic Lung Transplantation.
Matsumoto H; Suzuki H; Yamanaka T; Kaiho T; Hata A; Inage T; Ito T; Kamata T; Tanaka K; Sakairi Y; Motohashi S; Yoshino I
Life (Basel); 2023 Oct; 13(10):. PubMed ID: 37895424
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of a mycophenolic acid metabolite in patients with kidney failure negatively affect cardiomyocyte health.
Harlacher E; Schulte C; Vondenhoff S; Schmitt-Kopplin P; Diederich P; Hemmers C; Moellmann J; Wollenhaupt J; Veltrop R; Biessen E; Lehrke M; Peters B; Schlieper G; Kuppe C; Floege J; Jankowski V; Marx N; Jankowski J; Noels H
Front Cardiovasc Med; 2024; 11():1346475. PubMed ID: 38510194
[TBL] [Abstract][Full Text] [Related]
11. Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid.
Rong Y; Kiang T
Clin Pharmacokinet; 2023 Feb; 62(2):157-207. PubMed ID: 36848031
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy.
Chen XT; Li J; Deng RH; Yang SC; Chen YY; Chen PS; Wang ZY; Huang Y; Wang CX; Huang G
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30737303
[No Abstract] [Full Text] [Related]
13. Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid.
Nakano K; Iwami D; Yamada T; Morita K; Yasuda K; Shibuya H; Kahata K; Shinohara N; Shimizu C
Transplant Direct; 2018 Jan; 4(1):e337. PubMed ID: 29399626
[TBL] [Abstract][Full Text] [Related]
14. A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
Gard L; van Doesum W; Niesters HGM; van Son WJ; Diepstra A; Stegeman CA; Groen H; Riezebos-Brilman A; Sanders JS
PLoS One; 2017; 12(6):e0178801. PubMed ID: 28609473
[TBL] [Abstract][Full Text] [Related]
15. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.
Noreikaitė A; Saint-Marcoux F; Marquet P; Kaduševičius E; Stankevičius E
Medicine (Baltimore); 2017 Mar; 96(13):e6469. PubMed ID: 28353583
[TBL] [Abstract][Full Text] [Related]
16. Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.
McCune JS; Jacobson P; Wiseman A; Militano O
Bone Marrow Transplant; 2015 Feb; 50(2):165-72. PubMed ID: 25347008
[TBL] [Abstract][Full Text] [Related]
17. Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients.
Mazidi T; Rouini MR; Ghahremani MH; Dashti-Khavidaki S; Lessan-Pezeshki M; Ahmadi FL; Salam-Zadeh J; Mandegary A; Gholami K
Iran J Pharm Res; 2013; 12(3):547-56. PubMed ID: 24250661
[TBL] [Abstract][Full Text] [Related]
18. What do we learn from repeated population analyses?
Duffull SB; Wright DF
Br J Clin Pharmacol; 2015 Jan; 79(1):40-7. PubMed ID: 24033757
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
Abd Rahman AN; Tett SE; Staatz CE
Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
Johnson LA; Oetting WS; Basu S; Prausa S; Matas A; Jacobson PA
Eur J Clin Pharmacol; 2008 Nov; 64(11):1047-56. PubMed ID: 18568343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
